trending Market Intelligence /marketintelligence/en/news-insights/trending/e0k88qno2xwk-hqpvrs7dg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Novo Nordisk hemophilia A therapy maintains potency at high temperatures

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Novo Nordisk hemophilia A therapy maintains potency at high temperatures

Novo Nordisk A/S said a long-term study showed that its hemophilia A treatment, called NovoEight, maintained its potency even after being stored at temperatures of 40 degrees C.

Hemophilia A patients often struggle with treatment storage issues, the Danish drugmaker said in a news release.

SNL Image

The storage conditions for NovoEight allow the therapy to be stored at temperatures of up to 40 degrees for three months.